Insights into Hepatocellular Carcinoma (HCC) 2020 (Northeast)

Current treatment practice attitudes toward therapy of unresectable advanced hepatocellular carcinoma (HCC), recently introduced and upcoming agents

Northeast – August 19, 2020

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Scottsdale, AZ, USA

Example Report

Start discovering the insights

View Report


  • A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on the treatment of HCC was held on August 19, 2020, in a virtual setting
  • Disease state and data presentations were developed in conjunction with Dr Tanios Bekaii-Saab from Mayo Clinic Cancer Center
  • The group of advisors comprised community oncologists from the Northeast region of the United States
  • Insights on the following therapies were obtained: sorafenib, lenvatinib, cabozantinib, bevacizumab, atezolizumab, pembrolizumab, ramucirumab, ipilimumab, and nivolumab


  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • Attendees of the roundtable represented community oncologists from New Jersey, Massachusetts, Maryland, Vermont, and Pennsylvania

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.